Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma
Clinical trial NCT05189184 · UNKNOWN
Trial details
- NCT number
- NCT05189184
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-30
- Primary completion
- 2025-03-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.